ArticleCureus2022
A Pilot Study of Augmented Intelligence Risk-Based Stratification for Endocrine Surgical Waiting List Prioritisation.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence in Surgery: A Systematic Review of Use and Validation.Journal of clinical medicine · 2024Review
- The Use of Artificial Intelligence for Orthopedic Surgical Backlogs Such as the One Following the COVID-19 Pandemic: A Narrative Review.JB & JS open accessReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The New Deal for Surgery report encouraged using new technology in healthcare to address the 377,689 patients in England awaiting National Health Service (NHS) hospital treatment in July 2022. During the pandemic's second wave, this pilot study investigated the utility of COMPASS Surgical List Triage (COMPASS SLT; C2-Ai, Cambridge, England), an augmented intelligence-based system, in assisting surgical decision-making on patient prioritisation. Data generated from COMPASS SLT was compared to data from the British Association of Endocrine and Thyroid Surgeons' (BAETS) and Federation of Surgical Specialties Associations' (FSSA) prioritisation guidance. Methods A cohort of thyroidectomy and parathyroidectomy patients on the surgical waiting list at Imperial College Healthcare NHS Trust, London, United Kingdom, was used. COMPASS SLT calculated individuals' mortality and significant morbidity risk (risk >2.5%). Significant morbidity risk was set at 2.5% or above following internal model validation, thus reducing the risk of model overfitting occurring with COMPASS SLT. The additional increase in mortality and morbidity due to treatment delay was calculated. Actual treatment time was aligned to the treatment delay (in weeks) experienced by each patient. Results Twenty-nine patients, with a median age of 43 years and a waiting time of 18 weeks at the onset of the second wave, were enrolled. Non-statistically significant differences (p=0.937) between the FSSA and BAETS classifications were identified. However, cohort size could promote a type II error. An increase in median mortality and morbidity risk (p<0.001) arising from treatment delay and decisions based on the FSSA and BAETS classifications were identified. Conclusion COMPASS SLT can supplement clinical decision-making. An augmented intelligence tool can provide clinicians objectivity and flexibility in prioritising patients, with information on individual morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.